Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
about
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusionAnti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusionTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerNovel delivery strategies for glioblastomaClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionRole of platelet-derived growth factors in physiology and medicineSunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsDevelopment of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.Upregulation of thrombospondin-1 and angiogenesis in an aggressive human pancreatic cancer cell line selected for high metastasis.Use of antivascular endothelial growth factor for diabetic macular edema.Paeonol Inhibits Proliferation of Vascular Smooth Muscle Cells Stimulated by High Glucose via Ras-Raf-ERK1/2 Signaling Pathway in Coculture Model.Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signaling.Delivery of platelet-derived growth factor as a chemotactic factor for mesenchymal stem cells by bone-mimetic electrospun scaffolds.Platelet-derived growth factor over-expression in retinal progenitors results in abnormal retinal vessel formation.Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination.Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.Uveitic Macular Edema: Treatment Update.Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitorsZinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition.Platelet-derived growth factors and their receptors: structural and functional perspectives.Recruitment and retention: factors that affect pericyte migration.Expression Of Selected Pathway-Marker Genes In Human Urothelial Cells Exposed Chronically To A Non-Cytotoxic Concentration Of Monomethylarsonous Acid.The Role of PDGFs and PDGFRs in Colorectal Cancer.Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation.Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer.Giant cavernous hepatic hemangioma shrunk by use of sorafenib.Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition.Vascular stem/progenitor cells: functions and signaling pathways.The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
P2860
Q24194783-C38D7033-C05D-45B2-925A-2FD691E5C8D6Q24234625-6FB46332-7CEF-42C4-80D7-B124F1453B0EQ26862841-5D40109A-5046-49B4-A15A-A6B61C379218Q27006099-E9CA0127-62B9-4569-B5D6-396AB814ECC0Q28074834-F645D11A-06F8-4BC4-9F17-ED40A2621177Q29615222-BB8054CE-46B1-4AD5-A7E3-FD57FE0154B2Q33393174-E64DDD7B-E263-4F0E-94E9-5E13CEF806CEQ33457195-1E294836-0D36-4A18-A945-A4E2405EAFA7Q33479445-5A32F8B6-5F86-41DC-812F-3C5CCADA9FF6Q33599732-2E43EBE8-74A1-49DC-AA02-83F833F537A7Q33796768-69D3C180-CB3F-450A-AD13-1F8703A9A606Q34222231-322AB082-AB28-4EDB-BB9D-43E9BEFDD46DQ34342438-1D731413-5181-4F3D-8A01-DA1ED9EDD1BFQ34374175-AAA2F103-07BC-44E2-8AF6-F5544211FF59Q34786343-1EBDFA6F-FBBB-4E09-AC43-FA05B6153201Q34943946-B90A17FF-B438-4524-A066-E85B3B0CDF33Q35064469-9C71AF2C-DAF5-4EB0-9D43-FF8F32D583C4Q35837949-05EE49CE-5FF4-4744-BEDA-B88EEAA0F4E2Q35996229-3A01A96A-7959-42EE-8CCD-012D754FBB06Q36703169-1BB0A2CB-E883-4D12-AC04-DA4B3FBA0B9EQ36811817-F863D690-3DF3-4B83-B032-08C7431C7D60Q36903863-8C12D7C0-8A8D-4FAF-986C-744A4C4C63F9Q37029324-7D26C030-3835-408A-94F4-C32ADEF29CF4Q37293444-16F4C6BD-A04F-4FC4-BD8C-FBFAF94BC9F7Q37382109-1461372A-6302-4C87-B39D-5773C447554FQ37479305-3286C525-699F-4682-9BCD-3361EC54AE7BQ38058615-F81D2743-2886-4983-8D98-3E9040E649ACQ38126398-32B6834B-0327-43A8-9C8F-44489E4A8C09Q38960886-327936B4-3683-4950-B5CD-57CB9286C26FQ39120772-B5D155FC-B3D2-42D3-951F-A844334C8445Q39634834-574619A1-349F-40A4-B326-AF594EFF8514Q42222737-41730264-10F5-4832-94A5-B8D413F108E2Q43159026-8E2BADF9-0254-42E1-AB92-84AEC050F420Q43184381-5445EF9B-1CF5-47CD-97FE-09FB846F13F7Q48278651-88A08783-1D42-44B3-87A7-9D9753D64817Q57483233-8CD69661-8F45-4F9A-AFC0-0CD1F17662F4
P2860
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
@en
type
label
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
@en
prefLabel
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
@en
P2860
P1433
P1476
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
@en
P2093
Adil I Daud
Jade Homsi
P2860
P304
P356
10.1177/107327480701400312
P577
2007-07-01T00:00:00Z